News
Stay informed about the latest developments at Dr. Vince Clinical Research, from expanded capabilities and facility investments to industry insights and company news.
Explore the latest updates below, or contact us to learn how we can support your next study.
Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics’ CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients
Dr. Vince Clinical Research (DVCR), a full-service clinical research organization (CRO), today announced the first dosing in Cingulate Therapeutics’ CTx-1301 Phase…
Dr. Vince Clinical Research, Clario Form Strategic Partnership to Deliver Innovative Cardiac Assessments in Clinical Trials
OVERLAND PARK, Kan. & PHILADELPHIA, pa.; August 2023 – Dr. Vince Clinical Research (DVCR), an early phase Clinical Research Organization (CRO),…
Dr. Vince Clinical Research Joins the Fight Against the Fentanyl Crisis, Announces Screening of First Subject for Cessation Therapeutics’ Overdose Prevention Therapy in a First-In-Human Trial
OVERLAND PARK, Kan.; August 2, 2023 – Dr. Vince Clinical Research (DVCR), a full-service CRO specializing in Phase I-II clinical trials,…
Dr. Vince Clinical Research Now Green Certified
OVERLAND PARK, Kan.; June 27, 2023 (Business Wire) – Dr. Vince Clinical Research, a full-service Phase I-II contract research organization (CRO), announced…
Dr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics’ Phase 1 MAD Study of ATI-2138
OVERLAND PARK, KS; January 10, 2023—(BUSINESS WIRE) Dr. Vince Clinical Research (DVCR), an early phase CRO specializing in Phase 1 trials, announced…
Dr. Vince Clinical Research Strengthens Investigator Team with the Addition of George Atiee, MD
OVERLAND PARK, KS, December 12, 2022 (Globe Newswire) – Dr. Vince Clinical Research (DVCR) announced the addition of highly experienced investigator…
Dr. Vince Clinical Research Announces Dosing of Ensysce’s PF614 Compound in Human Abuse Potential Trial
OVERLAND PARK, Kan.; November 8, 2022 (ACCESSWIRE) – Dr. Vince Clinical Research (DVCR), a world-class early phase contract research organization (CRO) specializing…
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
Study Conducted by Dr. Vince Clinical Research KANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING),…
Dr. Vince Clinical Research Opens Industry-Leading Clinical Pharmacology Unit
OVERLAND PARK, Kan.–(BUSINESS WIRE)–Dr. Vince Clinical Research (DVCR), today announced the launch of its new, world-class clinical pharmacology unit and headquarters…
WCG IRB Expands Phase I Review Services, Partners with Dr. Vince Clinical Research
PRINCETON, N.J. & OVERLAND PARK, Kan.–(BUSINESS WIRE)–WCG, the world’s leading provider of solutions that measurably improve the quality and efficiency…